Vistagen Therapeutics Past Earnings Performance
Past criteria checks 0/6
Vistagen Therapeutics's earnings have been declining at an average annual rate of -18.2%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 17.6% per year.
Key information
-18.2%
Earnings growth rate
32.2%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 17.6% |
Return on equity | -26.0% |
Net Margin | -3,076.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis
Sep 08VistaGen drops 80% as late-stage study for anxiety therapy fails
Jul 22Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation
Apr 10VistaGen Therapeutics added to Russell 2000 Index
Jun 16VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business
Jun 07VistaGen initiates late-stage trial of PH94B in social anxiety disorder
May 26VistaGen names new chief commercial officer
May 04How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?
Feb 16VistaGen Therapeutics regains Nasdaq listing compliance
Jan 06VistaGen Therapeutics slumps in after hours trade on underwritten public offering
Dec 17VistaGen reports encouraging data differentiating mechanism of action of PH94B from benzodiazepines
Nov 12Revenue & Expenses BreakdownBeta
How Vistagen Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1 | -32 | 14 | 21 |
30 Sep 23 | 1 | -35 | 13 | 24 |
30 Jun 23 | 0 | -46 | 13 | 33 |
31 Mar 23 | 0 | -59 | 15 | 44 |
31 Dec 22 | 0 | -64 | 16 | 47 |
30 Sep 22 | 0 | -65 | 16 | 48 |
30 Jun 22 | 1 | -60 | 16 | 45 |
31 Mar 22 | 1 | -49 | 14 | 35 |
31 Dec 21 | 2 | -62 | 12 | 27 |
30 Sep 21 | 1 | -56 | 11 | 23 |
30 Jun 21 | 1 | -47 | 9 | 15 |
31 Mar 21 | 1 | -42 | 8 | 11 |
31 Dec 20 | 1 | -16 | 7 | 9 |
30 Sep 20 | 0 | -17 | 8 | 8 |
30 Jun 20 | 0 | -19 | 7 | 10 |
31 Mar 20 | 0 | -22 | 8 | 13 |
31 Dec 19 | 0 | -24 | 8 | 15 |
30 Sep 19 | 0 | -26 | 7 | 18 |
30 Jun 19 | 0 | -28 | 8 | 19 |
31 Mar 19 | 0 | -26 | 7 | 17 |
31 Dec 18 | 0 | -24 | 7 | 16 |
30 Sep 18 | 0 | -20 | 7 | 12 |
30 Jun 18 | 0 | -18 | 7 | 9 |
31 Mar 18 | 0 | -16 | 7 | 7 |
31 Dec 17 | 0 | -14 | 7 | 6 |
30 Sep 17 | 1 | -13 | 8 | 6 |
30 Jun 17 | 1 | -12 | 7 | 5 |
31 Mar 17 | 1 | -12 | 7 | 5 |
31 Dec 16 | 1 | -18 | 13 | 5 |
30 Sep 16 | 0 | -19 | 12 | 4 |
30 Jun 16 | 0 | -24 | 14 | 4 |
31 Mar 16 | 0 | -51 | 14 | 4 |
31 Dec 15 | 0 | -48 | 9 | 4 |
30 Sep 15 | 0 | -46 | 8 | 3 |
30 Jun 15 | 0 | -39 | 5 | 2 |
31 Mar 15 | 0 | -14 | 5 | 2 |
31 Dec 14 | 0 | -9 | 3 | 2 |
30 Sep 14 | 0 | -8 | 3 | 3 |
30 Jun 14 | 0 | -8 | 3 | 3 |
31 Mar 14 | 0 | -3 | 3 | 2 |
31 Dec 13 | 0 | -5 | 3 | 2 |
30 Sep 13 | 0 | -21 | 3 | 0 |
Quality Earnings: VTGN is currently unprofitable.
Growing Profit Margin: VTGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VTGN is unprofitable, and losses have increased over the past 5 years at a rate of 18.2% per year.
Accelerating Growth: Unable to compare VTGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VTGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: VTGN has a negative Return on Equity (-26.01%), as it is currently unprofitable.